The startup develops a handheld nanotechnology device that identifies unique genetic sequences in biological samples for the diagnosis of cancer, infectious diseases, and genetic disorders. This technology enables healthcare professionals to deliver targeted treatments based on precise genetic information, enhancing patient care and diagnostic accuracy.
Funding
Funding not disclosed
Founders
Product
Problem
Current methods for diagnosing cancer, infectious diseases, and genetic disorders often involve complex laboratory procedures and lengthy turnaround times. This can delay treatment decisions and increase patient anxiety.
Solution
The startup is developing a portable, handheld nanotechnology device designed for rapid identification of specific genetic sequences within biological samples. This point-of-care diagnostic tool aims to provide healthcare professionals with immediate access to critical genetic information, enabling faster and more informed treatment strategies. By streamlining the diagnostic process, the device seeks to improve patient outcomes through timely and targeted interventions. The technology has the potential to reduce the reliance on centralized labs, making genetic testing more accessible in diverse healthcare settings.
Target Audience
The primary target audience includes healthcare professionals, such as oncologists, infectious disease specialists, and genetic counselors, as well as hospitals, clinics, and research institutions.
Features
- Nanopore-based sequencing technology for direct analysis of genetic material
- Handheld form factor for point-of-care testing
- Real-time data analysis and result reporting
- Compatibility with various biological sample types
- Integrated software for data management and interpretation